Peginterferon and other interferons for hepatitis C - [Medication] - Quest Diagnostics Patient Health Library Topic Contents - Examples - How It Works - Why It Is Used - How Well It Works - Side Effects - What To Think About - References Peginterferon and other interferons for hepatitis C - [Medication] - Quest Diagnostics Patient Health Library Peginterferon and other interferons for hepatitis C - [Medication] - Quest Diagnostics Patient Health Library antiviral, antiviral...
Combination antiviral therapy for hepatitis C - [Medication] - Quest Diagnostics Patient Health Library Topic Contents - Examples - How It Works - Why It Is Used - How Well It Works - Side Effects - What To Think About - References Combination antiviral therapy for hepatitis C - [Medication] - Quest Diagnostics Patient Health Library Combination antiviral therapy for hepatitis C - [Medication] - Quest Diagnostics Patient Health Library antiviral, antiviral agents, Antiviral Drugs,...
Press Release - November 15, 2005 FOR IMMEDIATE RELEASE CONTACTS: Jerry Parrott Vice President, Corporate Communications 301/315-2777 Kate de Santis Director, Investor Relations 301/251-6003 HUMAN GENOME SCIENCES REPORTS INTERIM RESULTS OF PHASE 2 CLINICAL TRIAL OF ALBUFERON™ IN COMBINATION WITH RIBAVIRIN IN TREATMENT-EXPERIENCED HEPATITIS C PATIENTS ROCKVILLE, Maryland – November 15, 2005 – Human...
Press Release - October 25, 2005 The fourth treatment group serves as the active control group and receives weekly 180-mcg doses of subcutaneously administered Pegasys (peginterferon alfa -2a). Pegasys and 40 hours (22-60 hours) for PEG-Intron.Peginterferon alfa -2b plus...
Human Genome Sciences: Albuferon This compares to a reported mean elimination half-life of 80 hours (50-140 hours) for Pegasys and 40 hours (22-60 hours) for PEG-Intron.alfa -2a or alfa -2b with ribavirin in treatment naive patients with genotype 1 chronic hepatitis C.Peginterferon -alpha-2a ...
Viramidine (Valeant Pharmaceuticals), a ribavirin prodrug for the improved treatment of hepatitis C (HCV) infection: reduced - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
BIOPHARMA FDA Approvals - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
Cover 0519.qxd This weeks UK Patents and Design Journal (PDJ) contained details of one SPC grant and notification of three SPCs entering into force.peginterferon products, whilst in January 2003 ICN, Ribopharm and Roche agreed a settlement regarding pending patent litigation between the three companies...
author: GWhite
Cover 0519.qxd page 1
author: GWhite
Gazette Weekly Highlights News - Thomson Scientific Thomson.com - - - - - Advanced Search - - - EN : JP : CN : KR -- - - - Current Patents Gazette - Weekly Highlights News The gazette weekly highlights focuses on patent-related issues making the headlines, on noteworthy new applications, and on litigation and legislation affecting the industry.
Chronic viral hepatitis: B is for billions - Baraclude and Pegasys - new kids on the block increase options for physicians - This year has seen two new drug approvals: BMS's Baraclude (entecavir) gained US approval in March 2005 and Roche's Pegasys (peginterferon alfa -2a) was approved in the EU and the US in early 2005, after first being approved in Switzerland in late 2004.
Press Release - May 17, 2005 FOR IMMEDIATE RELEASE CONTACTS: Jerry Parrott Vice President, Corporate Communications 301/315-2777 Kate de Santis Director, Investor Relations 301/251-6003 HUMAN GENOME SCIENCES REPORTS RESULTS OF PRECLINICAL STUDY COMPARING ANTI-VIRAL ACTIVITY OF ALBUFERON™ AND THREE OTHER FORMS OF INTERFERON ALPHA USED TO TREAT HEPATITIS C - At clinically relevant patient serum...
Press Release - June 1, 2005 The fourth treatment group will serve as the active control group and will receive weekly 180-mcg doses of subcutaneously administered Pegasys (peginterferon alfa -2a). Pegasys and 40 hours (22-60 hours) for PEG-Intron.Peginterferon alfa -2b...
Press Release - April 13, 2005 FOR IMMEDIATE RELEASE CONTACT: Jerry Parrott Vice President, Corporate Communications 301/315-2777 Kate de Santis Director, Investor Relations 301/251-6003 Click here for more information on Albuferon HUMAN GENOME SCIENCES REPORTS POSITIVE RESULTS OF PHASE 2 CLINICAL TRIAL OF ALBUFERON™ IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C - Mean reduction in HCV viral load of 3...
No Title UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
author: Windows 9x/NT/2000/XP User
subject: None
No Title page 60
author: Windows 9x/NT/2000/XP User
subject: None
No Title page 12
author: Windows 9x/NT/2000/XP User
subject: None
http://www.amarbio.com/AJVR.pdf page 10
Vertex Pharmaceuticals Press Release May 25, 2004 Vertex Pharmaceuticals Announces Plans for the METRO Study: Triple Combination of Merimepodib, Pegasys® and Copegus® in Hepatitis C Patients - Roche Agrees to Provide Pegasys and Copegus for Phase IIb Clinical Trial - Cambridge, MA, May 25, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today the design of a Phase IIb clinical study that it plans to...
Therapeutic Biological Approvals 97 South Street Hopkinton, MA 01748 License 1258 02/05/1999 PEGASYS Peginterferon alfa -2a Treatment of adults with chronic hepatitis C who have compensated liver disease and who have not been previously treated with interferon alfa 103964 / 0 Hoffman-La Roche, Inc 340 Kingsland Street Nutley, NJ 07110-1199 License 0136 10/16/2002 PEGASYS ...
Office of Drug Safety: Patient Labeling and Risk Communitation Food and Drug Administration • Center for Drug Evaluation and Research Office of Drug Safety Search Patient Labeling and Risk Communication FDA-Approved Patient Labeling Patient Package Inserts.- For some prescription medicines, FDA approves special patient materials to instruct patients about the safe use of the product
author: PhillipsJ
Roche Investor Updates 2001 dollar denominated LYONs offering - Jul, 12 Roche announces placement of zero coupon convertible notes - Jul, 9 FDA approves Roche’s qualitative Amplicor HCV Test First approved PCR-based test to detect Hepatitis C Virus - Jul, 3 Shaping the future of genomic research with customized biochips Roche in strategic alliance with CombiMatrix Corporation, Subsidiary of Acacia Research...
Approved Biotechnology Drugs, 2000 Biotechnology Information, Advocacy and Business Support | About Us | BIO Events | BIO Members | Join BIO | Member Services | Links | Home CMS Payment System Prescription Coverage & Reimbursement Food & Agriculture Industrial & Environmental Bioethics & Biomedical Research Intellectual Property Regulatory Policies Tax & Fiscal Policies All Issues & Initiatives Press Releases Company...
Milestones 2003 Biotechnology Information, Advocacy and Business Support | About Us | BIO Events | BIO Members | Join BIO | Member Services | Links | Home CMS Payment System Prescription Coverage & Reimbursement Food & Agriculture Industrial & Environmental Bioethics & Biomedical Research Intellectual Property Regulatory Policies Tax & Fiscal Policies All Issues & Initiatives Press Releases Company...
CWW0745_Nov10.qxd page 6
author: Leslie
duplicates:http://www.phaseforward.com/news/media/2003_11_10.pdf
